Skip to main content
SpringerLink
Log in

Stereotactic Ablative Radiotherapy for Lung Cancers

  • Chapter
  • First Online:
Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies

  • 1105 Accesses

Abstract

Surgery is the treatment of choice in patients with early-stage non-small cell lung cancer (NSCLC). However, in patients who are medically inoperable or refuse to undergo surgery, radiotherapy (RT) is the alternative option. Although studies with conventional RT have revealed unsatisfactory results, stereotactic ablative RT (SABR) offers similar survival and disease control rates with surgery. Several dose-fractionation schemes have been studied, and the most important issue is to keep the biologically equivalent dose (BED) ≥100 when α/β is 10. Central and large lung tumors deserve extra caution while treating with SABR because of increased toxicity and decreased local control, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.

    Article  PubMed  Google Scholar 

  2. Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:161S–77.

    Article  PubMed  Google Scholar 

  3. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:119–30.

    Article  PubMed  Google Scholar 

  4. Sibley GS. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses – a review. Cancer. 1998;82:433–8.

    Article  CAS  PubMed  Google Scholar 

  5. Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–54.

    Article  CAS  PubMed  Google Scholar 

  6. Lagerwaard FJ, Senan S, van Meerbeeck JP, et al. Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer? Radiother Oncol. 2002;63:151–7.

    Article  PubMed  Google Scholar 

  7. Willner J, Baier K, Caragiani E, et al. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–9.

    Article  PubMed  Google Scholar 

  8. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24:31–7.

    Article  CAS  PubMed  Google Scholar 

  9. Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11.

    Article  PubMed  Google Scholar 

  10. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–28.

    Article  PubMed  Google Scholar 

  11. Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60:186–96.

    Article  PubMed  Google Scholar 

  12. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;49:23–33.

    Article  CAS  PubMed  Google Scholar 

  13. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861–70.

    Article  CAS  PubMed  Google Scholar 

  14. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–5.

    Article  PubMed  Google Scholar 

  15. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.

    Article  PubMed  Google Scholar 

  16. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–25.

    Article  PubMed  Google Scholar 

  17. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–92.

    Article  PubMed  Google Scholar 

  18. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–6.

    Article  PubMed  Google Scholar 

  19. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–82.

    Article  PubMed  Google Scholar 

  20. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.

    Article  PubMed  Google Scholar 

  21. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–55.

    Article  PubMed  Google Scholar 

  22. Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;91:344–50.

    Article  PubMed  Google Scholar 

  23. Kong C, Guo WJ, Zha WW, et al. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature. Lung Cancer. 2014;84:7–12.

    Article  PubMed  Google Scholar 

  24. Yu JB, Soulos PR, Cramer LD, et al. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer. 2015;121:2341–9.

    Article  PubMed  Google Scholar 

  25. Nakagawa K, Aoki Y, Tago M, et al. Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors: original research in the treatment of thoracic neoplasms. Int J Radiat Oncol Biol Phys. 2000;48:449–57.

    Article  CAS  PubMed  Google Scholar 

  26. Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82:1062–70.

    Article  CAS  PubMed  Google Scholar 

  27. Hiraoka M, Nagata Y. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience. Int J Clin Oncol. 2004;9:352–5.

    Article  PubMed  Google Scholar 

  28. Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2002;52:1041–6.

    Article  PubMed  Google Scholar 

  29. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–31.

    Article  PubMed  Google Scholar 

  30. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77:83–7.

    Article  PubMed  Google Scholar 

  31. Grills IS, Hope AJ, Guckenberger M, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7:1382–93.

    Article  PubMed  Google Scholar 

  32. Le QT, Loo BW, Ho A, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1:802–9.

    Article  PubMed  Google Scholar 

  33. Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol. 2012;102:383–7.

    Article  PubMed  Google Scholar 

  34. van der Voort van Zyp NC, Prevost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91:296–300.

    Article  Google Scholar 

  35. Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys. 2012;82:1149–56.

    Article  PubMed  Google Scholar 

  36. Kelley KD, Benninghoff DL, Stein JS, et al. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy. Radiat Oncol. 2015;10:120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Videtic GM, Hu C, Singh A, et al. Radiation Therapy Oncology Group (RTOG) protocol 0915: a randomized phase 2 study comparing 2 Stereotactic Body Radiation Therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;87:3.

    Article  Google Scholar 

  38. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6:2036–43.

    Article  PubMed  Google Scholar 

  40. Unger K, Ju A, Oermann E, et al. CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 2010;3:39.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 2009;66:89–93.

    Article  PubMed  Google Scholar 

  42. Nishimura S, Takeda A, Sanuki N, et al. Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol. 2014;9:1370–6.

    Article  CAS  PubMed  Google Scholar 

  43. Mangona VS, Aneese AM, Marina O, et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys. 2015;91:124–32.

    Article  PubMed  Google Scholar 

  44. Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys. 2014;88:1120–8.

    Article  PubMed  Google Scholar 

  45. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–95.

    Article  PubMed  Google Scholar 

  46. Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1–11.

    Article  PubMed  Google Scholar 

  47. Davis JN, Medbery 3rd C, Sharma S, et al. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol. 2015;4:55–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Allibhai Z, Taremi M, Bezjak A, et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;87:1064–70.

    Article  PubMed  Google Scholar 

  49. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215–22.

    Article  PubMed  Google Scholar 

  50. Shultz DB, Diehn M, Loo Jr BW. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer. Semin Radiat Oncol. 2015;25:78–86.

    Article  PubMed  Google Scholar 

  51. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–8.

    Article  PubMed  Google Scholar 

  52. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:348–53.

    Article  PubMed  Google Scholar 

  53. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–92.

    Article  PubMed  Google Scholar 

  54. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–51.

    Article  PubMed  Google Scholar 

  55. van der Voort van Zyp NC, Prevost JB, van der Holt B, et al. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2010;77:31–7.

    Article  Google Scholar 

  56. Zheng X, Schipper M, Kidwell K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90:603–11.

    Article  PubMed  Google Scholar 

  57. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol. 2009;4:1.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Takeda A, Sanuki N, Eriguchi T, et al. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;86:257–63.

    Article  PubMed  Google Scholar 

  59. Hayashi S, Tanaka H, Kajiura Y, et al. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol. 2014;9:138.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Thompson R, Giuliani M, Yap ML, et al. Stereotactic body radiotherapy in patients with previous pneumonectomy: safety and efficacy. J Thorac Oncol. 2014;9:843–7.

    Article  CAS  PubMed  Google Scholar 

  61. Stanic S, Paulus R, Timmerman RD, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88:1092–9.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5.

    Article  PubMed  Google Scholar 

  63. Voltolini L, Bongiolatti S, Luzzi L, et al. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. Eur J Cardiothorac Surg. 2013;43:e17–23.

    Article  PubMed  Google Scholar 

  64. Kato M, Shukuya T, Takahashi F, et al. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer. 2014;14:508.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102:335–42.

    Article  PubMed  Google Scholar 

  66. Palma DA, van Sornsen de Koste J, Verbakel WF, et al. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. Int J Radiat Oncol Biol Phys. 2011;81:974–8.

    Article  PubMed  Google Scholar 

  67. Pastis Jr NJ, Greer TJ, Tanner NT, et al. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Chest. 2014;146:406–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Takeda A, Kunieda E, Takeda T, et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:1057–65.

    Article  PubMed  Google Scholar 

  69. Singhvi M, Lee P. Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging. BMJ Case Rep. 2013. doi:10.1136/bcr-2012-007967.

    Google Scholar 

  70. Bollineni VR, Widder J, Pruim J, et al. Residual (1)(8)F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys. 2012;83:e551–5.

    Article  CAS  PubMed  Google Scholar 

  71. Huang K, Senthi S, Palma DA, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol. 2013;109:51–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit MD, Sezin Yuce Sari MD, Gozde Yazici MD, Pervin Hurmuz MD & Melis Gultekin MD

Authors
  1. Gokhan Ozyigit MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sezin Yuce Sari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gozde Yazici MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pervin Hurmuz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melis Gultekin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gokhan Ozyigit MD .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Hacettepe University, Faculty of Med., Ankara, Turkey

    Gokhan Ozyigit

  2. Department of Radiation Oncology, Koc University, Faculty of Medicine, Istanbul, Turkey

    Ugur Selek

  3. Department of Radiation Oncology, Baskent University School of Medicine, Adana, Turkey

    Erkan Topkan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ozyigit, G., Sari, S.Y., Yazici, G., Hurmuz, P., Gultekin, M. (2016). Stereotactic Ablative Radiotherapy for Lung Cancers. In: Ozyigit, G., Selek, U., Topkan, E. (eds) Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-28761-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28761-4_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28759-1

  • Online ISBN: 978-3-319-28761-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation